Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC).
Bernardo Leon Rapoport
No relevant relationships to disclose
Allen Poma
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Mary Lynne Hedley
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Robert E. Martell
Employment or Leadership Position - Tesaro
Stock Ownership - Tesaro
Rudolph M. Navari
No relevant relationships to disclose